The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus
- PMID: 24754003
- PMCID: PMC3992955
- DOI: 10.5681/apb.2014.031
The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus
Abstract
Metabolic disorders are a group of disorders, due to the disruption of the normal metabolic process at a cellular level. Diabetes Mellitus and Tyrosinaemia are the majorly reported metabolic disorders. Among them, Diabetes Mellitus is a one of the leading metabolic syndrome, affecting 5 to 7 % of the population worldwide and mainly characterised by elevated levels of glucose and is associated with two types of physiological event disturbances such as impaired insulin secretion and insulin resistance. Up to now, various treatment strategies are like insulin, alphaglucosidase inhibitors, biguanides, incretins were being followed. Concurrently, various novel therapeutic strategies are required to advance the therapy of Diabetes mellitus. For the last few decades, there has been an extensive research in understanding the metabolic pathways involved in Diabetes Mellitus at the cellular level and having the profound knowledge on cell-growth, cell-cycle, and apoptosis at a molecular level provides new targets for the treatment of Diabetes Mellitus. Receptor signalling has been involved in these mechanisms, to translate the information coming from outside. To understand the various receptors involved in these pathways, we must have a sound knowledge on receptors and ligands involved in it. This review mainly summarises the receptors and ligands which are involved the Diabetes Mellitus. Finally, researchers have to develop the alternative chemical moieties that retain their affinity to receptors and efficacy. Diabetes Mellitus being a metabolic disorder due to the glucose surfeit, demands the need for regular exercise along with dietary changes.
Keywords: Diabetes Mellitus; Ligands; Receptors; signalling.
Similar articles
-
Mitochondrial biogenesis: pharmacological approaches.Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. Curr Pharm Des. 2014. PMID: 24606795
-
Diabetes and branched-chain amino acids: What is the link?J Diabetes. 2018 May;10(5):350-352. doi: 10.1111/1753-0407.12645. Epub 2018 Feb 13. J Diabetes. 2018. PMID: 29369529
-
Protein Tyrosine Phosphatase 1B Inhibitors: A Novel Therapeutic Strategy for the Management of type 2 Diabetes Mellitus.Curr Pharm Des. 2019;25(23):2526-2539. doi: 10.2174/1381612825666190716102901. Curr Pharm Des. 2019. PMID: 31333090 Review.
-
Therapy for type 2 diabetes mellitus.WMJ. 1998 Mar;97(3):49-54. WMJ. 1998. PMID: 9540451 Review.
-
Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea.Diabetologia. 2012 Aug;55(8):2096-108. doi: 10.1007/s00125-012-2562-9. Epub 2012 May 4. Diabetologia. 2012. PMID: 22555472 Review.
Cited by
-
Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study.Niger Med J. 2017 Mar-Apr;58(2):63-67. doi: 10.4103/0300-1652.219348. Niger Med J. 2017. PMID: 29269983 Free PMC article.
-
New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27.Adv Pharm Bull. 2015 Dec;5(Suppl 1):599-603. doi: 10.15171/apb.2015.081. Epub 2015 Dec 31. Adv Pharm Bull. 2015. PMID: 26793604 Free PMC article.
-
A Comprehensive Review on Prospects of Polymeric Nanoparticles for Treatment of Diabetes Mellitus: Receptors-Ligands, In vitro & In vivo Studies.Recent Pat Nanotechnol. 2024;18(4):457-478. doi: 10.2174/1872210517666230803091245. Recent Pat Nanotechnol. 2024. PMID: 37534486 Review.
-
Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides.Toxins (Basel). 2020 May 10;12(5):313. doi: 10.3390/toxins12050313. Toxins (Basel). 2020. PMID: 32397648 Free PMC article. Review.
-
Swim Training Improves HOMA-IR in Type 2 Diabetes Induced by High Fat Diet and Low Dose of Streptozotocin in Male Rats.Adv Pharm Bull. 2015 Sep;5(3):379-84. doi: 10.15171/apb.2015.052. Epub 2015 Sep 19. Adv Pharm Bull. 2015. PMID: 26504760 Free PMC article.
References
-
- Samadder A, Chakraborty D, De A, Bhattacharyya SS, Bhadra K, Khuda-Bukhsh AR. Possible signaling cascades involved in attenuation of alloxan-induced oxidative stress and hyperglycemia in mice by ethanolic extract of Syzygium jambolanum: drug-DNA interaction with calf thymus DNA as target. Eur J Pharm Sci . 2011;44(3):207–17. - PubMed
-
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract . 2010;87(1):4–14. - PubMed
-
- Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health . 2009;63(4):332–6. - PubMed
Publication types
LinkOut - more resources
Full Text Sources